GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Cyclically Adjusted PB Ratio

Merus NV (Merus NV) Cyclically Adjusted PB Ratio : 9.78 (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Merus NV Cyclically Adjusted PB Ratio?

As of today (2024-05-01), Merus NV's current share price is $47.02. Merus NV's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $4.81. Merus NV's Cyclically Adjusted PB Ratio for today is 9.78.

The historical rank and industry rank for Merus NV's Cyclically Adjusted PB Ratio or its related term are showing as below:

MRUS' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 5.93   Med: 9.21   Max: 10.77
Current: 9.35

During the past years, Merus NV's highest Cyclically Adjusted PB Ratio was 10.77. The lowest was 5.93. And the median was 9.21.

MRUS's Cyclically Adjusted PB Ratio is ranked worse than
88.98% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs MRUS: 9.35

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Merus NV's adjusted book value per share data for the three months ended in Dec. 2023 was $6.162. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.81 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Merus NV Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Merus NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Cyclically Adjusted PB Ratio Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 5.72

Merus NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 5.72

Competitive Comparison of Merus NV's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Merus NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus NV's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merus NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Merus NV's Cyclically Adjusted PB Ratio falls into.



Merus NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Merus NV's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=47.02/4.81
=9.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merus NV's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Merus NV's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=6.162/126.4000*126.4000
=6.162

Current CPI (Dec. 2023) = 126.4000.

Merus NV Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.687 98.360 0.883
201406 0.000 99.240 0.000
201409 0.000 99.960 0.000
201412 -0.281 99.050 -0.359
201503 0.000 99.750 0.000
201506 -0.611 100.230 -0.771
201509 2.493 100.500 3.135
201512 2.173 99.730 2.754
201603 1.846 100.310 2.326
201606 4.729 100.260 5.962
201609 4.447 100.570 5.589
201612 2.225 100.710 2.793
201703 5.030 101.440 6.268
201706 4.291 101.370 5.351
201709 3.614 102.030 4.477
201712 3.494 101.970 4.331
201803 5.198 102.470 6.412
201806 4.744 103.100 5.816
201809 4.341 103.950 5.279
201812 4.532 103.970 5.510
201903 4.177 105.370 5.011
201906 3.731 105.840 4.456
201909 3.289 106.700 3.896
201912 4.546 106.800 5.380
202003 3.950 106.850 4.673
202006 3.453 107.510 4.060
202009 2.906 107.880 3.405
202012 3.236 107.850 3.793
202103 6.180 108.870 7.175
202106 5.699 109.670 6.568
202109 5.330 110.790 6.081
202112 7.275 114.010 8.066
202203 6.831 119.460 7.228
202206 7.121 119.050 7.561
202209 6.453 126.890 6.428
202212 5.335 124.940 5.397
202303 4.694 124.720 4.757
202306 5.163 125.830 5.186
202309 6.814 127.160 6.773
202312 6.162 126.400 6.162

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merus NV  (NAS:MRUS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Merus NV Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Merus NV's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV (Merus NV) Business Description

Industry
Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Executives
Harry Shuman officer: Chief Accounting Officer C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman officer: EVP & General Counsel C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg director, officer: President, CEO & PFO C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De officer: Chief Technology Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy director C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen director
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki director 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W officer: SVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe officer: SVP, CMO C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby officer: EVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM

Merus NV (Merus NV) Headlines

From GuruFocus

Merus to Participate in Upcoming Investor Conferences

By Stock market mentor Stock market mentor 02-01-2023

Merus Announces Business Update Conference Call

By GlobeNewswire 10-16-2023